期刊文献+

枸橼酸舒芬太尼喷鼻用于术后镇痛的临床观察 被引量:1

Clinical research of intranasal sufentanil citrate for postoperative analgesia
暂未订购
导出
摘要 目的探讨枸橼酸舒芬太尼喷鼻用于术后镇痛的有效性和安全性。方法选取50例ASAⅠ或Ⅱ级椎管内麻醉下腹部手术后的女性患者,将枸橼酸舒芬太尼经鼻腔给药,每位患者左右各1喷(每喷量为100μL,2喷含舒芬太尼10μg),观察各时间点的疼痛评分、血压、心率、SpO2和不良反应。结果舒芬太尼喷鼻后,94%的患者术后疼痛得到明显的缓解,5~10 min后疼痛明显减轻,30 min时接近最大镇痛效应,有效时间至少持续120 min,HR、SBP、DBP、SpO2无显著变化,未发生明显不良反应。结论枸橼酸舒芬太尼喷鼻用于术后镇痛,疗效确切,效果显著。成人10μg/次(2喷)的舒芬太尼是比较合适的剂量,未发生明显不良反应。 Objective To evaluate the safety and efficacy of intranasal sufentanil citrate for postoperative analgesia.Methods Fifty female patients,ASA I–II,scheduled for abdominal operation under intrathecal anesthesia,were included when postoperative pain treatment was required.A nasal puff device delivering a constant volume of 100μL was used.Each patient received a dose of 10μg/2 puff.Evaluation of pain intensity(and analgesic effect) and adverse reactions were recorded.Blood pressure,heart rate and pulse oximetry were also recorded.Results After nasal administration of 10μg/2 puff sufentanil,94% of the patients attained satisfactory analgesia at least 120min,with onset of pain relief after 5-10min and efficacy achieved after 30 min.Blood pressure,heart rate and oxygen saturation remained stable throughout the observation period without remarkable adverse reactions.Conclution Intranasally administered sufentanil citrate offer a rapid,effective method of postoperative analgesia without remarkable adverse event.A dose of 10μg/2 puff of sufentanil may be suitable in an adult patient.
出处 《中国医药科学》 2011年第13期13-14,共2页 China Medicine And Pharmacy
基金 广东省医学科研基金(编号:A2007226)
关键词 枸橼酸舒芬太尼 经鼻给药 术后镇痛 Sufentanil citrate Nasal administration Postoperative analgesia
  • 相关文献

参考文献8

二级参考文献69

  • 1王红珠,王惠琴.不同浓度舒芬太尼用于术后静脉自控镇痛的比较[J].临床医学,2007,27(1):28-29. 被引量:22
  • 2吴镜湘,陈明,赵丽丽,梁昌毅,徐美英.胸科手术后舒芬太尼静脉镇痛的剂量探讨[J].临床麻醉学杂志,2007,23(1):22-23. 被引量:50
  • 3Illum L. Nasal drug delivery: new developments and strategies [J]. Drug Discov Today ,2002,7(23): 1184 - 1189.
  • 4Illum L. Nasal drug delivery-possibilities, problems and solu tions[ J ]. J Controlled Release, 2003,87 ( 1 - 3): 187 - 198.
  • 5Torchilin VP.Drug targeting[J].Eur J Pharm Sci,2000,11(Suppl 2):S81-S91.
  • 6Cornford EM, Cornford ME. New systems for delivery of drugs to the brain in neurological disease[ J ]. Lancet Neurol, 2002,1 (5) :306-315.
  • 7Sakane T, Akizuki M, Yamashita S, et al. Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs[J]. J Pharm Pharmacol, 1995, 47(5) :379 - 381.
  • 8Born J, Lange T, Kern W. Sniffing neuropeptides: a transnasal approach to the human brain[J]. Nat Neurosci, 2002,5(6):514 - 516.
  • 9Persson E, Henriksson J, Tjalve H. Uptake of cobalt from the nasal mucosa into the brain via olfactory pathways in rats [ J ]. Toxicol Lett, 2003,145 ( 1 ): 19 - 27.
  • 10Illum L. Transport of drugsfromthe nasal cavity to the central nervous system[J].EurJPharm Sci,2000,11(1):1-18.

共引文献73

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部